Given the multiple lines of evidence supporting HER2 expression in human prostate tumors and the potency of HER2 inhibition in PCa cell lines (see Figure 6B), we next asked whether HER2 inhibition had an antitumor effect in human patient–derived PCa models. The gene discussed is ERBB2; the disease is prostate neoplasm.